IFNA1 and Behcet disease: The objective of treatment is prevention of irreversible organ damage, especially in the early and active phase of BD, targeting the clinical manifestations, and management is dependent on the severity of involvement of the organ in question.5 Antagonists of tumor necrosis factor alpha (TNF-α) and interferon (IFN) have demonstrated good efficacy and are the first-line agents used to improve BD prognosis.